{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:03:15Z","timestamp":1792159395484,"version":"4.4.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). However, reported associations were inconsistent, and it remains unknown if semaglutide or tirzepatide is associated with other disorders of the optic nerve and visual pathways.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine associations of treatment with either semaglutide or tirzepatide with first-time diagnoses of optic nerve and visual pathway disorders in patients with type 2 diabetes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study emulated target trials based on a nationwide, population-based database of US patient electronic health records from December 2017 to January 2023. Models were adjusted by propensity score matching. Eligible patients had type 2 diabetes and no prior diagnosis of eye disorders and were prescribed semaglutide, tirzepatide, or other antidiabetic medications.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Prescription of semaglutide or tirzepatide vs other antidiabetic medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other glucagon-like peptide 1 receptor agonists).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>First-time diagnoses of NAION and other optic nerve disorders during a 2-year follow-up were examined using Cox proportional hazards and Kaplan-Meier survival analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>After propensity score matching among 1\u202f511\u202f637 eligible patients, the study population comprised 159\u202f398 matched patients with type 2 diabetes (mean [SD] age, 56.5 [13.3] years; 83\u202f123 women [52.15%]), including 79\u202f699 patients in the semaglutide or tirzepatide group and 79\u202f699 patients in the comparison group. During the 2-year follow-up, there were 35 patients (0.04%) with NAION in the semaglutide or tirzepatide group and 19 patients (0.02%) with NAION in the matched comparison group (hazard ratio, 1.76 [95% CI, 1.01-3.07]). There were 93 patients (0.12%) with other optic nerve disorders in the semaglutide or tirzepatide group and 54 patients (0.07%) with other optic nerve disorders in the matched comparison group (hazard ratio, 1.65 [95% CI, 1.18-2.31]). No association was found with other disorders of the optic nerve or visual pathways.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of NAION and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.26327","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:00:23Z","timestamp":1754924423000},"page":"e2526327","source":"Crossref","is-referenced-by-count":55,"title":["Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes"],"prefix":"10.1001","volume":"8","author":[{"given":"Lindsey","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora D.","family":"Volkow","sequence":"additional","affiliation":[{"name":"National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, North Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[{"name":"Center for Clinical Informatics Research and Education, MetroHealth System, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"3","key":"zoi250741r1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes.","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"key":"zoi250741r2","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"zoi250741r3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10402","key":"zoi250741r4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"zoi250741r5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi250741r6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"zoi250741r7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials.","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"zoi250741r8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"zoi250741r9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview.","volume":"7","author":"Salvetat","year":"2023","journal-title":"Vision (Basel)"},{"issue":"3","key":"zoi250741r10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41433-023-02873-6","article-title":"Correction: NAION or not NAION: a literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies.","volume":"38","author":"Martin-Gutierrez","year":"2024","journal-title":"Eye (Lond)"},{"issue":"8","key":"zoi250741r11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"zoi250741r12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy.","volume":"142","author":"Mollan","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"zoi250741r13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study.","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"issue":"3","key":"zoi250741r14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide.","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"zoi250741r15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy.","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"zoi250741r16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials.","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"zoi250741r18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"zoi250741r19","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-02716-8","article-title":"How rival weight-loss drugs fare at treating obesity, diabetes and more.","author":"Lenharo","year":"2024","journal-title":"Nature"},{"issue":"12","key":"zoi250741r23","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US.","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi250741r24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes. target trial emulation using real-world data.","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi250741r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250741r26","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"zoi250741r27","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"1","key":"zoi250741r28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"zoi250741r29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","volume":"117","author":"Wang","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi250741r30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity.","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi250741r31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes.","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"issue":"7","key":"zoi250741r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes.","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250741r33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.618353","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large scale meta-analysis.","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"zoi250741r36","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy.","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"zoi250741r38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"zoi250741r39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","article-title":"Pathogenesis of nonarteritic anterior ischemic optic neuropathy.","volume":"23","author":"Arnold","year":"2003","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"zoi250741r40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis.","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10","key":"zoi250741r41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/jmg.35.10.793","article-title":"Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy.","volume":"35","author":"Votruba","year":"1998","journal-title":"J Med Genet"},{"key":"zoi250741r42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/EB.S69174","article-title":"Papilledema: epidemiology, etiology, and clinical management.","volume":"7","author":"Rigi","year":"2015","journal-title":"Eye Brain"},{"issue":"9","key":"zoi250741r43","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye.","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"zoi250741r44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.exer.2018.05.021","article-title":"The polymorphisms of ATOH 7, ET-1 and ACE in non-arteritic anterior ischemic optic neuropathy.","volume":"174","author":"Chen","year":"2018","journal-title":"Exp Eye Res"},{"key":"zoi250741r34","volume-title":"StatPearls","author":"Raizada","year":"2025"},{"key":"zoi250741r35","volume-title":"A Package for Survival Analysis in R: R Package: Version 2","author":"Therneau","year":"2015"},{"key":"zoi250741r17","unstructured":"TriNetX Engineering. Function propensity_score_matching. Accessed December 17, 2024. https:\/\/lucid.trinetx.com\/r\/v1.0\/reference\/propensity_score_matching.html"},{"key":"zoi250741r20","unstructured":"Novo Nordisk. Ozempic prescribing information. Accessed June 27, 2024. https:\/\/www.ozempic.com\/prescribing-information.html"},{"key":"zoi250741r21","unstructured":"Lilly. Mounjaro (tirzepatide) injection and Zepbound (tirzepatide) injection. Accessed March 3, 2025. https:\/\/tirzepatide.lilly.com\/"},{"key":"zoi250741r22","unstructured":"TriNetX. Real-world data. TriNetX. Accessed January 16, 2024. https:\/\/trinetx.com\/real-world-data\/"},{"key":"zoi250741r37","unstructured":"Tamhankar? M, Volpe? NJ. Nonarteritic anterior ischemic optic neuropathy: epidemiology, pathogenesis, and etiologies. UpToDate. Accessed July 5, 2024. https:\/\/www.uptodate.com\/contents\/nonarteritic-anterior-ischemic-optic-neuropathy-epidemiology-pathogenesis-and-etiologies"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837377\/wang_2025_oi_250741_1753982854.39358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:00:25Z","timestamp":1754924425000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26327","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}